Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 10/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035309 | 0.87 | ICMT (0.51) | ICMTCNR1NR1D1KAT2BMAPT | |
| SCHEMBL3585665 | 0.85 | ICMT (0.50) | ICMTCNR1MAPTCNR2 | |
| SCHEMBL28131233 | 0.84 | ICMT (0.55) | ICMTCNR1MAPTCNR2RXFP1 | |
| SCHEMBL4038440 | 0.84 | NR4A2 (0.49) | ICMTMAPT | |
| SCHEMBL28131995 | 0.77 | ICMT (0.47) | ICMTCNR1MAPT | |
| SCHEMBL24143060 | 0.75 | ICMT (0.45) | ICMTCNR1CNR2 | |
| SCHEMBL10193361 | 0.72 | CNR1 (0.46) | ICMTCNR1CNR2 | |
| SCHEMBL24143098 | 0.72 | ICMT (0.42) | ICMTNR1D1KAT2BMAPT | |
| SCHEMBL3596003 | 0.72 | ICMT (0.46) | ICMTCNR1CNR2 | |
| SCHEMBL3588680 | 0.72 | ICMT (0.46) | ICMTCNR1KAT2BMAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | PTGER1, PTGER2, PTGER3 | ICMT 946/4885CNR1 7/4885NR1D1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.